This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Additional points to consider before incorporating the Food and Drug Administration–approved therapies for systemic sclerosis–associated interstitial lung disease: comment on the article by Khanna et al. Issue 4 (21st February 2022)
Record Type:
Journal Article
Title:
Additional points to consider before incorporating the Food and Drug Administration–approved therapies for systemic sclerosis–associated interstitial lung disease: comment on the article by Khanna et al. Issue 4 (21st February 2022)
Main Title:
Additional points to consider before incorporating the Food and Drug Administration–approved therapies for systemic sclerosis–associated interstitial lung disease: comment on the article by Khanna et al